The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer

BACKGROUND: Over recent years a number of novel therapies have shown promise in advanced renal cell carcinoma (RCC). Internationally the standard of care of first-line therapy is sunitinib™, after a clear survival benefit was demonstrated over interferon-α. Convention dictates that sunitinib is cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Collinson, Fiona J, Gregory, Walter M, McCabe, Chris, Howard, Helen, Lowe, Catherine, Potrata, DrBarbara, Tubeuf, Sandy, Hanlon, Pat, McParland, Lucy, Wah, T, Selby, Peter J, Hewison, Jenny, Brown, Julia, Brown, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583710/
https://www.ncbi.nlm.nih.gov/pubmed/23241439
http://dx.doi.org/10.1186/1471-2407-12-598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583710/
https://www.ncbi.nlm.nih.gov/pubmed/23241439
http://dx.doi.org/10.1186/1471-2407-12-598

Ejemplares similares